Cell line · CVCL_6642
Papers27
1 more article gives this line's RRID in its Methods without naming the line nearby, so it is not listed.
1 to 20 of 27
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Collagen-Binding IL-15 Immunocytokine Armed Oncolytic Adenovirus Establishes a Self-Reinforcing Immunostimulatory Milieu to Potentiate Antitumor Immunity. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| An Integrin β6-Targeted Antibody-Drug Conjugate Optimized for Intravesical Delivery to Treat Non-Muscle-Invasive Bladder Cancer. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Neutralizing human monoclonal antibodies that target the PcrV component of the type III secretion system of Pseudomonas aeruginosa act through distinct mechanisms. | Elife | 2026 | Its Methods give the RRID and name the line | PubMed | |
| PD-L1-Binding Antigen Presenters: Redirecting Vaccine-Induced Antibodies for Cancer Immunotherapy. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
Molecular mechanism of resistance to lonafarnib conferred by mutations in the cysteine-rich region of respiratory syncytial virus fusion glycoprotein and discovery of a lonafarnib-derived antiviral PROTAC. | J Virol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| SLC7A11-specific CAR-T cell therapy potently targets colorectal and pancreatic cancer. | iScience | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Cancer-associated fibroblasts expressing FSTL3 promote vasculogenic mimicry formation and drive colon cancer malignancy. | Cell Death Dis | 2025 | Its Methods give the RRID and name the line | PubMed | |
| A long-lasting prolactin stimulates galactopoiesis in mice. | iScience | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Cytoplasmic delivery of antibodies through grafting a functional single complementarity-determining region loop. | FEBS Lett | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Efficacy of natural killer T and gammadelta T cells in mesothelin-targeted immunotherapy of pancreatic cancer. | Front Immunol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Target-agnostic identification of human antibodies to Plasmodium falciparum sexual forms reveals cross-stage recognition of glutamate-rich repeats. | Elife | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Control of mitophagy initiation and progression by the TBK1 adaptors NAP1 and SINTBAD. | Nat Struct Mol Biol | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Eliciting a single amino acid change by vaccination generates antibody protection against group 1 and group 2 influenza A viruses. | Immunity | 2024 | Its Methods give the RRID and name the line | PubMed | |
| An engineered immunocytokine with collagen affinity improves the tumor bioavailability, tolerability, and therapeutic efficacy of IL-2. | Cell Rep Med | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Secreted ORF8 induces monocytic pro-inflammatory cytokines through NLRP3 pathways in patients with severe COVID-19. | iScience | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Human immunoglobulin repertoire analysis guides design of vaccine priming immunogens targeting HIV V2-apex broadly neutralizing antibody precursors. | Immunity | 2022 | Its Methods give the RRID and name the line | PubMed | |
| Structural basis of nanobodies neutralizing SARS-CoV-2 variants. | Structure | 2022 | Its Methods give the RRID and name the line | PubMed | |
| Functional development of a V3/glycan-specific broadly neutralizing antibody isolated from a case of HIV superinfection. | Elife | 2021 | Its Methods give the RRID and name the line | PubMed | |
| Comparison of Two Strategies to Generate Antigen-Specific Human Monoclonal Antibodies: Which Method to Choose for Which Purpose? | Front Immunol | 2021 | Its Methods give the RRID and name the line | PubMed | |
| A Human IgSF Cell-Surface Interactome Reveals a Complex Network of Protein-Protein Interactions. | Cell | 2020 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_6642/papers